closes an oversubscribed financing round

Swiss-Israeli digital health start-up AG reports that it has seen a large interest in its current post-seed financing round after which it announced the closing of an oversubscribed funding round. Existing shareholders and new investors made their contributions.

The Swiss-Israeli digital health start-up was incorporated in 2017 by Yves Nordmann and Ulrich Muehlner to develop personalized healthcare solutions that enable the paradigm shift from volume-based to value-based healthcare. The HIPAA- and GDPR (DSGVO)-compliant cloud-based platform docdok for synchronous and asynchronous communication between healthcare providers and patients is deeply integrated into the primary software systems used in healthcare.

The company has found the product-market fit for its docdok platform within a top-notch partner and customer ecosystem. Among its customers and partners are two of the top ten hospitals in the world (Sheba Medical Center in Israel and University Hospital Zurich in Switzerland), several leading pharmaceutical companies, international medical associations, and tech firms like IBM. Doctors in outpatient facilities also rely on the solution. The startup is already active in five countries.

In the wake of the COVID-19 pandemic, the start-up saw a rising need for digital health solutions which resulted in its rapid growth. By using docdok both in everyday clinical practice and for studies, docdok uniquely closes the communication and information gap between patients and the main players in the health care system and improves patient care by collecting and providing patient-generated health data.

Fresh capital to boost further growth
Existing shareholders and new investors have also seen great potential in the company’s offering, hence their participation in the newly concluded oversubscribed financing round.

CEO and Co-Founder Ulrich Muehlner states: “The new funding will be mainly used to accelerate the international roll-out of our docdok platform and to on-board key hires. Furthermore, we have an exciting product pipeline of digital health applications and digital therapeutics addressing major unmet needs that we will launch over the next 12 months.”

(Press release/RAN)